The trends driving ELRIG Drug Discovery 2022
Drug Discovery World
OCTOBER 4, 2022
The trial will see Bayer using its subsidiary BrainVectis to investigate its gene therapy, BV-101 in the treatment for Huntington’s Disease (HD). As a project, it demonstrated the importance of collaboration between industry and academia to solve the remarkable challenge of developing a vaccine in record time. .
130 
Let's personalize your content